Chen Xiaofang, Li Ningyu, Weng Jianyu, Du Xin
Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
School of Medicine, South China University of Technology, Guangzhou, China.
Front Cell Dev Biol. 2021 Feb 11;8:617466. doi: 10.3389/fcell.2020.617466. eCollection 2020.
Myelodysplastic syndrome (MDS) is a group of clonal hematopoietic disorders related to hematopoietic stem and progenitor cell dysfunction. However, therapies that are currently used to target hematopoietic stem cells are not effective. These therapies are able to slow the evolution toward acute myeloid leukemia but cannot eradicate the disease. Mesenchymal stem cells (MSCs) have been identified as one of the main cellular components of the bone marrow microenvironment, which plays an indispensable role in normal hematopoiesis. When functional and regenerative capacities of aging MSCs are diminished, some enter replicative senescence, which promotes inflammation and disease progression. Recent studies that investigated the contribution of bone marrow microenvironment and MSCs to the initiation and progression of the disease have offered new insights into the MDS. This review presents the latest updates on the role of MSCs in the MDS and discusses potential targets for the treatment of MDS.
骨髓增生异常综合征（MDS）是一组与造血干细胞和祖细胞功能障碍相关的克隆性造血疾病。然而，目前用于靶向造血干细胞的疗法并不有效。这些疗法能够减缓向急性髓系白血病的进展，但无法根除该疾病。间充质干细胞（MSCs）已被确定为骨髓微环境的主要细胞成分之一，在正常造血过程中发挥着不可或缺的作用。当衰老的间充质干细胞的功能和再生能力减弱时，一些细胞进入复制性衰老，这会促进炎症和疾病进展。最近研究骨髓微环境和间充质干细胞对该疾病发生和进展的贡献的研究为骨髓增生异常综合征提供了新的见解。本综述介绍了间充质干细胞在骨髓增生异常综合征中作用的最新进展，并讨论了治疗骨髓增生异常综合征的潜在靶点。
